Bristol, AbbVie drug extends multiple myeloma remission-study

May 13 (Reuters) - The addition of an experimental Bristol-Myers Squibb biotech medicine to standard therapy for patients whose multiple myeloma has relapsed led to longer remissions and cut the risk of death over standard treatment alone, according to data from a late stage study.